Author

Dominik Naessens 1

1 Janssen-Cilag,Beerse,Belgium

ASSESSING THE LEVEL OF UNMET NEED AMONGST ULCERATIVE COLITIS PATIENTS IN THE UNITED STATES AND EUROPE

Jim Kershaw, James Lucas, Dominik Naessens

DIFFERENT INDUCTION RESPONSE CRITERIA DO NOT INFLUENCE 1 YEAR RESPONSE AND REMISSION RATES OF USTEKINUMAB 90 MG Q8W IN PHASE III PROGRAM

Dominik Naessens, Jewel Johanns, Christopher Gasink

Indirect treatment comparison of ustekinumab versus other advanced therapies in moderate to severe ulcerative colitis after 1 year

Margaux Welty, Laura Mesana, Amie Padhiar, Dominik Naessens, Joris Diels, Suzy van Sanden, Maud Pacou

INDIRECT TREATMENT COMPARISON OF USTEKINUMAB VERSUS OTHER BIOLOGICS IN MODERATE-TO-SEVERE CROHN'S DISEASE PATIENTS HAVING FAILED ANTI-TNF THERAPY ‒ A 1-YEAR TREATMENT SEQUENCE ANALYSIS INCLUDING DELAYED RESPONDERS

Laura Mesana, Maud Pacou, Dominik Naessens, Sheldon Sloan, Aline Gauthier

INDIRECT TREATMENT COMPARISON OF USTEKINUMAB VERSUS OTHER BIOLOGICS IN MODERATE-TO-SEVERE CROHN'S DISEASE PATIENTS HAVING FAILED CONVENTIONAL THERAPY ‒ A 1-YEAR TREATMENT SEQUENCE ANALYSIS INCLUDING DELAYED RESPONDERS

Laura Mesana, Maud Pacou, Dominik Naessens, Sheldon Sloan, Aline Gauthier

Ustekinumab Improved Work Productivity in Patients with Moderate to Severe Ulcerative Colitis: Results from the Phase 3 UNIFI Induction and Maintenance Studies

Dominik Naessens, Chenglong Han, Hongyan Zhang, Jewel Johanns, Colleen W. Marano, Bruce E. Sands

USTEKINUMAB IMPROVES PRODUCTIVITY AND REDUCES WORK LIMITATION OF PATIENTS WITH MODERATE TO SEVERE CROHN'S DISEASE: RESULTS FROM THREE PHASE 3 CLINICAL TRIALS

Bruce E. Sands, Chenglong Han, Dominik Naessens, Christopher Gasink, Douglas Jacobstein, L.L. Gao, Brian G. Feagan

WEIGHT DISTRIBUTION IN EUROPEAN PATIENTS WITH CROHN?S DISEASE IN ADELPHI 2015 DSP

Dominik Naessens, Ben Hoskin, James Lucas

Item 1 - 8 / 8
1